Meet our Team

Our leadership team has the clinical expertise and commercial acumen to identify, innovate, and commercialize a diversified portfolio of high-margin products in attractive markets with experience in direct-to-consumer (DTC), physician, and professional market development to drive adoption of our medical technologies toward standard of care.



Chief Executive Officer

Lishan Aklog, M.D. has served as Lucid’s Chairman and Chief Executive Officer since its IPO in October 2021 and previously served as its Executive Chairman since its inception in 2018. Dr. Aklog also co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception.



Chief Financial Officer

Dennis M. McGrath has served as the Company’s Executive Vice President and Chief Financial Officer since March 2017.

Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. 

pavmed-David Wurtman_round.png


Chief Medical Officer

David Wurtman, M.D., M.B.A. is an entrepreneurial leader focused on making biopharmaceutical assets and technologies more valuable.  He has held industry leadership roles for over 20 years, most recently serving as President, CEO, and, Member of the Board of Directors of Lyric Pharmaceuticals, a clinical-stage pharmaceutical company he co-founded in 2013. 



Chief Commercial Officer

Shaun M. O’Neil has served as the Company’s Chief Commercial Officer since July 2018.

As Lucid's Chief Commercial Officer he is responsible for the planning and execution of both sales and marketing activities for the U.S., Europe, South America, and Asia. His responsibilities include the development of Lucid Dx’s strategic partnerships, distribution channels, creation of growth strategies and successful business solutions for branding and positioning of the product lines as well as organize, develop, and grow the sales organization. 

Lucid-Randy Brown_round.png


Executive Vice President Clinical Development and Operations

Randy Brown is a seasoned Clinical Development executive with nearly 30 years of global device and drug development.  He most recently served as the global head of clinical operations at Baxter Healthcare, an $11 billion dollar medical device company.  Mr. Brown has led several clinical development programs in over 30 countries resulting in multiple approvals.  From 2015-2018 he served as the Vice President of Clinical Operations for Lyric Pharmaceuticals – a clinical-stage pharmaceutical company focused on a critical care compound.  Randy has spent several years in various leadership roles within Clinical Development/Operations of well-known organizations such as Davita, Anaclim/Spherix, and Eli Lilly.  He has played key roles in several approvals throughout his career.



Strategic Advisor

Stan Lapidus is an inventor and entrepreneur who currently serves on a number of healthcare and medical technology boards. 


He’s been founding CEO of three medical diagnostics companies. Two of them have been among the most successful diagnostics startups of all time: 


Cytyc Corp., which he founded in 1987, revolutionized early detection of cervical cancer through its development of the modern Pap test—the ThinPrep. The two ThinPrep prototypes are at the Smithsonian’s American Museum of National History. 


EXACT Sciences, which he founded in 1995, pioneered non-invasive early detection of colorectal cancer through its Cologuard test. Since its introduction, Cologuard has become the fastest-growing test in the history of the diagnostics industry.

In the News

See the latest news and press coverage from Lucid Diagnostics